IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Small Cell Lung Cancer: Is It Time for Biomarker-directed Therapy?
January 11, 2018 | Online

Overview

For the past four decades, advances of any nature in the management of small cell lung cancer (SCLC) have been elusive, and the grim prognosis for patients diagnosed with this disease remained unchanged. However, this scenario appears to be changing significantly. There are now several areas where scientific and clinical progress is evident.  This webinar will highlight recent advances in the understanding of the biology of SCLC and the use of targeted therapies in clinical practice.

  • Dr. Ready will address SCLC from histology to molecular characterization and assess delta-like protein  (DLL3) as a therapeutic target.  
  • Dr. Owonikoko will discuss the issue of tissue-based profiling of SCLC in the real-world and examine the value of Tumor Mutational Burden (TMB) as a predictive biomarker for immunotherapy in SCLC.

What you should expect to learn

At the conclusion of this activity, participants will:

  • Recognize therapeutic agents for SCLC.
  • Identify new, biomarker testing to direct treatment decisions.
  • Increase familiarity with state of the art SCLC management algorithms

Taofeek K. Owonikoko, MD, PhD

Vice Chair for Faculty Development
Associate Director, Hematology/Oncology
Fellowship Training Program
Department of Hematology and Medical Oncology
Emory Univesity School of Medicine
Winship Cancer Institute
Atlanta, Georgia

&

Neal E. Ready, MD, PhD

Professor of Medicine
Member of Duke Cancer Institute, Duke School of Medicine
Durham, North Carolina

Contact